Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603178 | 0.89 | REN (0.37) | RENSCN9ANR1H2NR1H3 | |
| SCHEMBL7639116 | 0.88 | REN (0.47) | RENRXRAARALDH1A1MAPT | |
| SCHEMBL7606437 | 0.88 | REN (0.44) | RENRXRASCN9AALDH1A1MAPT | |
| SCHEMBL12354177 | 0.84 | RXRA (0.37) | RENRXRASCN9AARALDH1A1 | |
| SCHEMBL7603142 | 0.84 | REN (0.44) | RENRXRASCN9AALDH1A1MAPT | |
| SCHEMBL7604334 | 0.82 | REN (0.41) | RENSCN9AALDH1A1MAPTRECQL | |
| SCHEMBL7601619 | 0.81 | SCN9A (0.33) | RENSCN9AARNR1H2NR1H3 | |
| SCHEMBL7606450 | 0.81 | REN (0.44) | RENRXRAALDH1A1MAPTRECQL | |
| SCHEMBL7601596 | 0.79 | REN (0.44) | RENRXRASCN9AALDH1A1MAPT | |
| SCHEMBL7602315 | 0.78 | REN (0.53) | RENRXRAALDH1A1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885RXRA 1477/4885SCN9A 1426/4885 |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885RXRA 3258/4885SCN9A 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.